The effect of attendance in the Dutch breast cancer screening program on breast tumor characteristics among migrant women by R.R.E. Dassen, S. Pelders, L. de Munck, A. Jager, M.J. Hooning, J.H. van Dam, B.A.M. Heemskerk-Gerritsen

Get full text

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade by M. C. Liefaard, A. van der Voort, M. van Seijen, B. Thijssen, J. Sanders, S. Vonk, L. Mittempergher, R. Bhaskaran, L. de Munck, A. E. van Leeuwen-Stok, R. Salgado, H. M. Horlings, E. H. Lips, G. S. Sonke

Get full text

The INFLUENCE 3.0 model: Updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy by M.C. Van Maaren, T.A. Hueting, D.J.P. van Uden, M. van Hezewijk, L. de Munck, M.A.M. Mureau, P.A. Seegers, Q.J.M. Voorham, M.K. Schmidt, G.S. Sonke, C.G.M. Groothuis-Oudshoorn, S. Siesling

Get full text

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer by M. C. Liefaard, A. van der Voort, M. S. van Ramshorst, J. Sanders, S. Vonk, H. M. Horlings, S. Siesling, L. de Munck, A. E. van Leeuwen, M. Kleijn, L. Mittempergher, M. M. Kuilman, A. M. Glas, J. Wesseling, E. H. Lips, G. S. Sonke

Get full text